Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulmatrix Inc PULM

Healthcare
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as... see more

Recent & Breaking News (NDAQ:PULM)

20 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  February 7, 2017

15 Biggest Mid-Day Gainers For Monday

Benzinga.com  February 6, 2017

The Biotech Market Grows as Demand for New Therapeutics Increases

PR Newswire February 6, 2017

Pulmatrix Announces Over $3.0 Million Registered Direct Offering

PR Newswire February 3, 2017

22 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  February 2, 2017

Pulmatrix Announces $5 Million Registered Direct Offering

PR Newswire January 30, 2017

25 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  January 27, 2017

Mid-Afternoon Market Update: Crude Oil Up 1.2%; Progress Software Shares Plunge

Benzinga.com  January 17, 2017

15 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  January 17, 2017

Pulmatrix Drug Candidate Receives "Qualified Infectious Disease Product" (QIDP) Designation from the FDA

PR Newswire January 17, 2017

Improving the Lives of Patients with Respiratory Diseases

Marketwired December 20, 2016

Pulmatrix Receives Patents Important to its Inhaled Drug Delivery Technology

PR Newswire December 19, 2016

Pulmatrix Chief Scientific Officer David Hava Featured on Health Media Now

PR Newswire November 29, 2016

20 Biggest Mid-Day Losers For Friday

Benzinga.com  November 4, 2016

Pulmatrix Reports Third Quarter 2016 Financial Results and Business Update

PR Newswire November 4, 2016

Pulmatrix Will Present Promising New Data at the North American Cystic Fibrosis Conference on October 27-29, 2016

PR Newswire October 11, 2016

Pulmatrix Highlights Recent Report Predicting Rapid Growth for Inhaled Drug Delivery Methods

PR Newswire September 23, 2016

Stocks Hitting 52-Week Lows

Benzinga.com  August 30, 2016

Pulmatrix Receives Orphan Drug Designation from the FDA for Inhaled Drug to Treat Pulmonary Fungal Infections in Cystic Fibrosis Patients

PR Newswire August 17, 2016

Breathing Easier: Pharma Successfully Leveraging Smoother EU Regulatory Specs

Canada NewsWire August 11, 2016